Our identification of novel HLA-I-presented ZIKV epitopes sheds light on cytotoxic CD8 + T cell activation to contribute to the growing knowledge of how ZIKV can be employed as an immunotherapy, and may assist in the development of novel epitope-specific immunotherapies against brain tumours. This evidence concerns the gene CD8A and brain neoplasm.